Approval · Notice of Compliance 9209 · 2007
EXELON PATCH 10: Notice of Compliance 9209
Issued November 29, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9209
- Date
- November 29, 2007
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH 10 | 02302853 | Marketed |
| EXELON PATCH 5 | 02302845 | Marketed |
Medicinal ingredients
- RIVASTIGMINE 9 MG per 5SQCM
- RIVASTIGMINE 18 MG per 10SQCM